Targeting immune cells in pancreatic cancer treatment
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer
This study is looking at new ways to help people with pancreatic cancer by focusing on certain immune cells in the tumor area and testing a special treatment that could boost the body's natural defenses against the cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rockefeller University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11078756 on NIH RePORTER |
What this research studies
This research focuses on improving treatments for pancreatic cancer by targeting specific immune cells in the tumor microenvironment. The approach involves studying the role of a receptor called MARCO and testing antibodies that block this receptor to enhance the immune response against tumors. By understanding how these immune cells can be repolarized, the research aims to develop new immunotherapies that could be more effective for patients with pancreatic cancer. Patients may benefit from innovative therapies that could improve their treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer who may benefit from new immunotherapy approaches.
Not a fit: Patients with other types of cancer or those who do not have pancreatic cancer may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapies for pancreatic cancer patients.
How similar studies have performed: While immunotherapy has shown success in other cancers, the specific approach of targeting MARCO in pancreatic cancer is relatively novel and has not been extensively tested.
Where this research is happening
New York, United States
- Rockefeller University — New York, United States (Active)
Researchers
- Principal investigator: Ravetch, Jeffrey Victor — Rockefeller University
- Study coordinator: Ravetch, Jeffrey Victor
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.